Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that the US Food and Drug Administration (FDA) has approved its Yartemlea ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
Company enters 2026 focused on disciplined expansion, national partnerships, and scalable solutions to the growing ...
HausVorteil AG, founded in 2021, is a real estate company specializing in portfolio growth and capital release. The company offers innovative recapitalization products as well as professional ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Today’s energies support restructuring your financial priorities. Reassessing your budget to ensure it aligns with current ...
Rehmann CEO Stacie Kwaiser is planning for the New Year as the Top 50 Firm deals with the many changes from the past year.
Australian explorers continue to build momentum across a range of commodities, with recent updates highlighting progress in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback